Literature DB >> 36125615

Effect of Berberine on Activation of TLR4-NFκB Signaling Pathway and NLRP3 Inflammasome in Patients with Goat.

Wan-Tai Dang1, Dan Xu2, Jing-Guo Zhou1.   

Abstract

OBJECTIVE: To determine the effects of berberine (BBR) on the activation of toll-like receptor 4 (TLR4), nuclear factor (NF)κB (NF-κB) signaling and NLRP3 inflammasome in patients with gout.
METHODS: Peripheral blood mononuclear cells (PBMCs) were obtained from 24 acute (AP) and 41 non-acute (NAP) phases of primary gout patients, respectively, as well as 30 healthy controls (HC). TLR4, NF-κB (p65), NLRP3, apoptosis-associated specklike protein containing a CARD (PYCARD), cysteinyl aspartate specific proteinase-1 (CASP1), and interleukin-1β (IL-1β) mRNA expression levels in PBMCs were measured by quantitative reverse transcriptase polymerase chain reaction. The protein levels of TLR4, myeloid differentiation factor 88 (MyD88), NF-κB (p50/65), inhibitor of kappa B kinase α/β (IKKα/β), NF-κB inhibitor α (IKBα), phospho-IKKα/β (p-IKKα/β), NLRP3, PYCARD, and CASP1 were monitored by Western blotting. Serum IL-1β protein level was measured using enzyme-linked immunosorbent assay (ELISA). In addition, PBMCs from HC and macrophages derived from a spontaneously immortalized monocyte-like cell line (THP-1) were stimulated using monosodium urate (MSU, 100 µg/mL), 0.1% dimethyl sulfoxide, 25 µmol/L BBR, and 10, 25, and 50 µmol/L BBR+100 µg/mL MSU for different time periods. The protein levels of IL-1β and IL-18 in cell culture supernatants was measured by ELISA, and the protein expressions of TLR4, MyD88, NF-κB (p50/p65), IKKα/β, I κBβ, p-IKKα/β, NLRP3, PYCARD, and CASP1 in macrophages were analyzed by Western blotting.
RESULTS: (1) TLR4, NF-κB (p65), PYCARD, CASP1, and IL-1β mRNA levels in PBMCs were significantly higher in the AP group than in the HC group (P<0.05). The NLRP3 mRNA expression levels in PBMCs were found to be significantly lower in the AP and NAP groups than in the HC group (P<0.05, P<0.01). (2) The protein levels of TLR4, IKKβ, MyD88, NF-κB, p-IKKα/β, PYCARD, and CASP1 in PBMCs were significantly higher, and those of IκBα, IKKα, and NLRP3 were found to be significantly lower in the AP group than in the HC group (P<0.05 or P<0.01). (3) The serum IL-1β protein levels were significantly higher in the AP and NAP groups than in the HC group (P<0.01). (4) The IL-1β protein level was significantly lower in the culture supernatants of the PBMCs stimulated with MSU for 3 and 6 h in the 25 and 50 µmoL/L BBR groups compared with that in the MSU group (P<0.01). (5) The protein levels of IL-1β and IL-18 were also significantly lower in the culture supernatants of macrophages stimulated with MSU for 3 and 6 h in BBR groups compared with those in the MSU group (P<0.01). (6) The protein levels of TLR4, MyD88, NF-κB (p50, p65, p105), IKKα/β, p-IκBα, p-IKKα/β, PYCARD, and CASP1 were significantly differed between the macrophages stimulated with MSU for 0.5 and 6 h in BBR groups compared with those in the MSU group (P<0.05 or P<0.01).
CONCLUSIONS: Activation of TLR4-NFκB signaling and NLRP3 inflammasome by MSU crystals drives the progression of gout inflammation. BBR ameliorates gouty inflammation, which is mechanistically associated with its regulation of TLR4-NF-κB signaling and NLRP3 inflammasome expression.
© 2022. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  NLRP3 inflammasome; TLR4-NF-κB; berberine; gout; monosodium urate

Year:  2022        PMID: 36125615     DOI: 10.1007/s11655-022-3720-7

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   2.626


  32 in total

1.  Risk of vascular disease with gout: overadjustment of the statistical analyses?

Authors:  Caroline M van Durme; Bart Spaetgens; Annelies Boonen; Frank de Vries
Journal:  Ann Rheum Dis       Date:  2014-10-21       Impact factor: 19.103

2.  Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation.

Authors:  Xin Cai; Jueqi Chen; Hui Xu; Siqi Liu; Qiu-Xing Jiang; Randal Halfmann; Zhijian J Chen
Journal:  Cell       Date:  2014-03-13       Impact factor: 41.582

Review 3.  Gout.

Authors:  Nicola Dalbeth; Hyon K Choi; Leo A B Joosten; Puja P Khanna; Hirotaka Matsuo; Fernando Perez-Ruiz; Lisa K Stamp
Journal:  Nat Rev Dis Primers       Date:  2019-09-26       Impact factor: 52.329

4.  Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome.

Authors:  Yiqing Yan; Wei Jiang; Lei Liu; Xiaqiong Wang; Chen Ding; Zhigang Tian; Rongbin Zhou
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

Review 5.  Gout.

Authors:  Pascal Richette; Thomas Bardin
Journal:  Lancet       Date:  2009-08-17       Impact factor: 79.321

6.  Identification and analysis of alkaloids in cortex Phellodendron amurense by high-performance liquid chromatography with electrospray ionization mass spectrometry coupled with photodiode array detection.

Authors:  Xiaoyan Xian; Bohang Sun; Xueting Ye; Guanying Zhang; Pengyi Hou; Huiyuan Gao
Journal:  J Sep Sci       Date:  2014-05-02       Impact factor: 3.645

7.  Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury.

Authors:  Chien-Cheng Chen; Tai-Ho Hung; Chao Yu Lee; Liang-Fei Wang; Chun-Hu Wu; Chia-Hua Ke; Szu-Fu Chen
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

8.  2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Tuhina Neogi; Tim L Th A Jansen; Nicola Dalbeth; Jaap Fransen; H Ralph Schumacher; Dianne Berendsen; Melanie Brown; Hyon Choi; N Lawrence Edwards; Hein J E M Janssens; Frédéric Lioté; Raymond P Naden; George Nuki; Alexis Ogdie; Fernando Perez-Ruiz; Kenneth Saag; Jasvinder A Singh; John S Sundy; Anne-Kathrin Tausche; Janitzia Vaquez-Mellado; Steven A Yarows; William J Taylor
Journal:  Ann Rheum Dis       Date:  2015-10       Impact factor: 19.103

9.  Inhibition of IRE1α RNase activity reduces NLRP3 inflammasome assembly and processing of pro-IL1β.

Authors:  Aaron Talty; Shane Deegan; Mila Ljujic; Katarzyna Mnich; Serika D Naicker; Dagmar Quandt; Qingping Zeng; John B Patterson; Adrienne M Gorman; Matthew D Griffin; Afshin Samali; Susan E Logue
Journal:  Cell Death Dis       Date:  2019-08-16       Impact factor: 8.469

10.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Authors:  Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.